Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

IMPORTANT IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs

Coordinator
Orebro Lans Landsting, Sweden
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€5.4m
Total cost
€5.4m
Partners
21 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101104589

What the project is doing

In the project's own words, from its summary on CORDIS.

Current evidence from both randomized trials and real-world evidence studies suggests that older breast cancer patients derive clinical benefit from the addition of CDK 4/6-inhibitors to endocrine therapy but with higher risk for adverse events and treatment discontinuation compared to younger patients. The IMPORTANT project will design and conduct a pragmatic clinical study with a decentralised approach for older patients with advanced breast cancer aiming at high level of evidence (level I) with multi-layer results that can enable changes in current clinical practice.

This study will be conducted across 6 (six) EU countries, and will include more than 500 female and male patients. The project will also perform a series of analyses over a) a wide range of clinical-relevant primary and secondary endpoints targeting to contribute to current clinical practice and b) the implementation of specific strategies aiming at more individualized treatment and follow-up approaches to a clinical trial setting that highly resembles real-world setting due to the trial's pragmatic design.

The project will be developed in 60 months by a competitive consortium of 19 partners from 11 countries, which corresponds to a well-balanced structure, involving clinical sites, SMEs, universities and patient advocacy organizations. Despite the great diversity of entities within the proposal, IMPORTANT partners bring state-of-the-art complementary skills ensuring the ability of the consortium to successfully complete the proposed work.

This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Topics

Who is involved

OrganisationCityCountryRole
Orebro Lans LandstingOrebroSwedenCoordinator
Circular Economy FoundationBrusselsBelgiumParticipant
Fachhochschule Nordwestschweiz FhnwWindischSwitzerlandAssociatedpartner
Elliniki Synergazomeni Ogkologiki OmadaAthensGreeceParticipant
Panepistimio PatronRio PatrasGreeceParticipant
Phaze Kliniki Erevna & Farmakeftikes Symvoules Anonymi EtaireiaAthinaGreeceParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Universidad Nacional De Educacion a DistanciaMadridSpainParticipant
Hus-YhtymaHelsinkiFinlandParticipant
Eunomia LimitedDublinIrelandParticipant
Security Labs Consulting LimitedCorkIrelandParticipant
Azienda Ospedaliero-Universitaria CareggiFirenzeItalyThird party
Azienda Unita' Sanitaria Locale Toscana CentroFirenzeItalyParticipant
Universita Degli Studi Di FirenzeFlorenceItalyParticipant
Institute for Medical Technology Assessment BVRotterdamNetherlandsParticipant
Akershus Universitetssykehus HfLorenskogNorwayParticipant
BrostcancerforbundetStockholmSwedenParticipant
Orebro UniversityOrebroSwedenThird party
Region UppsalaUppsalaSwedenParticipant
Care Across LtdLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI